Giants vs. Jets Face-Off: Treatment Options and the Present Status of Non-Small Cell Lung Tumors in Patients who Test Positive for ALK

An outline of the debate, the speakers, and the basic guidelines to support the program.

Results of phase 3 ALTA-1L study comparing crizotinib with Brigatinib in advanced ALK-positive non-small cell lung cancer

EGFR-mutated stage IB-IIIA non-small cell lung carcinoma that has been removed and treated with adjuvant osimertinib.

Osimertinib monotherapy as the standard of treatment for frontline EGFR mutant advanced NSCLC will be replaced by combination therapies.

Discussion on the treatment for borderline resectable patients with NSCLC.

Discussion regarding immunotherapy alone or in combination with chemotherapy for patients with NSCLC that are PD-L1 >50%.

Conclusion of the discussion and award presentation.

The CROWN and ADURA trials were discussed and defended as part of a non–small cell lung cancer Face Off.